



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : McComsey et al

Serial No. : 10/606,422

Art Unit: 1653

Filed

: JUNE 26, 2003

Examiner: LUKTON, DAVID

For

: SUBSTITUTED HETEROCYCLIC ACYL-TRIPEPTIDES USEFUL AS

THROMBIN RECEPTOR MODULATORS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

NOVEMBER 2, 2006
(Date of Deposit)

YURIY P. STERCHO, PH.D. (Name of applicant, assignee, or Registered Representative)

(\$lightaure)

NOVEMBER 2, 2006

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement filed on January 15, 2005 and the First Supplemental Information Disclosure Statement filed on February 10, 2006.

The Examiner did not consider two references cited in the First Supplemental IDS, specifically Derian, C. et al., "Vascular Occlusion in Non-Human Primates" and Mouse, S., "Antiplatelet therapies: from aspirin to GPIIIb/IIIa-receptor antagonist and beyond."

Applicants herewith submit these references for consideration by the Examiner.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified

application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In acco	ordance with §1.129(a), this Information
Disclosure Stateme	ent is being filed in connection with [] the
first or 🗌 second	After Final Submission, therefore:
St	catement in Accordance with §1.97(e) (attached);
01	c
P]	lease charge Deposit Account No. 10-
07	750/ORT1222(DIV)/YS the fee of <u>\$180.00</u> as set
fo	orth in §1.17(p).
☐ In acco	ordance with §1.97(c), this Information
Disclosure Stateme	ent is being filed after the period set forth in
§1.97(b) above but	t before the mailing date of either a Final

Action under §1.	113 or a Notice of Allowance under §1.311, or an
action that other	rwise closes prosecution and that it is
accompanied by o	one of:
	Statement in Accordance with §1.97(e) (attached);
П	Please charge Deposit Account No. 10-
	0750/ORT1222(DIV)/YS the fee of \$180.00 as set
	forth in §1.17(p).
☐ In ac	cordance with §1.97(d), this Information
Disclosure State	ment is being filed after the mailing date of
either a Final A	ction under §1.113 or a Notice of Allowance under
§1.311 but befo	re the payment of the Issue Fee. Applicant(s)
hereby petition(s) for consideration of this Information
Disclosure State	ment. Included are: Statement in Accordance with
§1.97(e) as set	forth below and the fee of $$180.00$ as set forth in
§1.17(p).	
	s of each of the references listed on the attached re enclosed herewith.
	s of references listed on the attached Form PTO-
	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
	If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
	s of only foreign patent documents and non-patent nclosed in accordance with 37 CFR 1.98 (a)(2).

There are no listed references which are not in the
English language.
The relevance of those listed references which are not
in the English language is as follows:
☐ Attached are copies of search report(s) from
corresponding patent application(s), which are listed on the
attached Submission Under MPEP 609 D.
Copies of the references listed on the search report(s)
are included except for those previously cited in an IDS mailed
Attached are the following non-published pending patent
applications which may be deemed relevant, which are listed on the
attached Submission Under MPEP 609 D.
Please charge any deficiency or credit any overpayment to
Deposit Account No. 10-0750/ORT1222(DIV)/YS. This form is
submitted in triplicate.
Respectfully submitted,
YURIY P. STERCHO, PH.D.
Reg. No. 33,797
Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (610) 240-8006 DATED: NOVEMBER 2, 2006 NOA 0 8 5000 F

SUBMISSION UNDER MPEP 609 D 2nd Supplemental IDS Page 1 of 1

Application Number	10/606,422
Filing Date	June 26, 2003
First Named Inventor	McComsey
Group Art Unit	1653
Examiner Name	LUKTON, DAVID
Attorney Docket Number	ORT 1222(DIV)

		U.S. PA	TENT DOCUMENTS	<u> </u>		
			U.S. Patent Docur	nent	Pages, Columns, Lines, where relevant passages or	
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Kind Code ²			
miliais			Number	(if known)	relevant figures appear	
	<u> </u>					
	 			<u> </u>		
	-					
	ļ	-				
			<u> </u>			
	ŀ					
	<u> </u>	FOREIGN I	PATENT DOCUMEN	NTS		

			NPATENT				
Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Foreign Pa	Number ⁴	KindCode ⁵	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
						v	
						74	
				ļ			
	ļ						••••
			·				
		OTHER PRIOR ART - N					
Examiner 's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T²		
		MOUSA, SHAKER, "Antiplatelet thera Therapeutic Focus, Elsevier Science Lt					
		DERIAN ET AL, "Blockage of the Thror Antagonist Prevents Thrombus Forma of Pharmacology and Experimental T Society for Pharmacology and Experim	nbin Receptor tion and Vas herapeutics*,	or Protease-A cular Occlus 2003, PP 8	ctivated Rece ion in Non-Hu	ptor-1 with a Small Molecule man Primates", The Journal	
···		<u> </u>					

Examiner		Date	
Signature	, ,	Considered	